<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491127</url>
  </required_header>
  <id_info>
    <org_study_id>6899</org_study_id>
    <secondary_id>B9E-XM-S315</secondary_id>
    <nct_id>NCT00491127</nct_id>
  </id_info>
  <brief_title>Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase II Study of Cisplatin With Gemcitabine in Fixed Dose Rate Infusion and Dexamethasone in Second-Line in Patients With Aggressive Non-Hodgkin’s Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study it to evaluate efficacy of gemcitabine with cisplatin and
      dexamethasone in patients with aggressive non-Hodgkin's lymphoma who have previously
      progressed on first line of chemotherapy with anthracyclines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression - free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease - free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients must have a histological diagnosis of aggressive non-Hodgkin’s lymphoma
             including the following sub-categories of the WHO classification:

               -  Diffuse large B-cell lymphoma and its variants (immunoblastic, Burkitt-like,
                  sclerosis of mediastinum, large B-cell MALT, rich in T-cells and anaplastic
                  B-cell lymphoma)

               -  Peripheral T-cell lymphoma

               -  Anaplastic lymphoma of large T-cells /null cells

          -  Patients are eligible if they have documented evidence of progression after prior
             first-line chemotherapy containing anthracyclines associated or not with Rituximab.
             Patients with refractory disease to first line of treatment are also eligible.

          -  ECOG PS (performance status) less than or equal to 2

          -  Presence of bidimensionally measurable disease in accordance with WHO criteria.

        Exclusion Criteria:

          -  Involvement of the CNS.

          -  Any medical condition which contraindicates the degree of hydration required for the
             safe use of cisplatin.

          -  Intermediate degree lymphoma derived from the malignant transformation of a previous
             low-grade lymphoma.

          -  Active infection (in the opinion of the investigator).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2007</study_first_posted>
  <last_update_submitted>June 21, 2007</last_update_submitted>
  <last_update_submitted_qc>June 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

